Overview

An Open-Label, Phase 1 Study in Healthy Adult Subjects to Examine the Effects of Multiple-Dose Ciprofloxacin on Ivacaftor and VX-661 in Combination With Ivacaftor

Status:
Completed

Trial end date:
2014-02-01

Target enrollment:

Participant gender:

Summary

To evaluate the effect of ciprofloxacin on the pharmacokinetics (PK) of ivacaftor and on the pharmacokinetics of VX-661 when administered in combination with ivacaftor

Phase:

Phase 1

Details

Lead Sponsor:

Vertex Pharmaceuticals Incorporated

Treatments:

Ciprofloxacin
Ivacaftor